SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, has reported its results for the first quarter and confirmed all targets for the fiscal year 2025.
“Our long-term growth fields, including biologics, GLP-1, ADCs and the shift from intravenous to subcutaneous administration, continue to show extraordinary growth,” said Andreas Reisse, CEO of SCHOTT Pharma. “We are actively driving these through additionally secured long-term contracts and projects. With our unique market position and well-progressing ramp-ups, we foresee a good second half of our fiscal year 2025. Everything is set for another strong year.”
“Following a very successful year 2024, we expected a softer start into 2025 and will now use our strong foundation to reach our full year targets,” said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma. “The additional capacities in glass syringes and sterile cartridges combined with secured contracts will drive the business performance in the second half of the year.”
The full report is available here.